StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

BioXcel Therapeutics total assets

Total assets on the balance sheet at the end of each period.

BioXcel Therapeutics's total assets was $28.80M at Jun 30, 2026. For fiscal 2025 it was $44.92M, up 17.2% from the year before. The highest annual figure on record is $239.44M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$44.92M+17.2%
FY2024Dec 31, 2024$38.34M-48.0%
FY2023Dec 31, 2023$73.70M-64.2%
FY2022Dec 31, 2022$205.85M-14.0%
FY2021Dec 31, 2021$239.44M+8.9%
FY2020Dec 31, 2020$219.94M+504.4%
FY2019Dec 31, 2019$36.39M-16.4%
FY2018Dec 31, 2018$43.55M+3113.9%
FY2017Dec 31, 2017$1.36M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$28.80M+11.7%
Q1 FY2026Mar 31, 2026$34.03M-11.8%
Q4 FY2025Dec 31, 2025$44.92M+17.2%
Q3 FY2025Sep 30, 2025$44.79M-8.4%
Q2 FY2025Jun 30, 2025$25.79M-60.6%
Q1 FY2025Mar 31, 2025$38.57M-53.2%
Q4 FY2024Dec 31, 2024$38.34M-48.0%
Q3 FY2024Sep 30, 2024$48.89M-51.3%
Q2 FY2024Jun 30, 2024$65.44M-53.3%
Q1 FY2024Mar 31, 2024$82.32M-54.3%
Q4 FY2023Dec 31, 2023$73.70M-64.2%
Q3 FY2023Sep 30, 2023$100.45M-59.0%
Q2 FY2023Jun 30, 2023$140.10M-43.6%
Q1 FY2023Mar 31, 2023$180.10M-14.7%
Q4 FY2022Dec 31, 2022$205.85M-14.0%
Q3 FY2022Sep 30, 2022$244.82M-6.3%
Q2 FY2022Jun 30, 2022$248.24M-11.7%
Q1 FY2022Mar 31, 2022$211.05M+5.3%
Q4 FY2021Dec 31, 2021$239.44M+8.9%
Q3 FY2021Sep 30, 2021$261.33M+9.5%
Q2 FY2021Jun 30, 2021$281.11M+298.9%
Q1 FY2021Mar 31, 2021$200.39M+133.5%
Q4 FY2020Dec 31, 2020$219.94M+504.4%
Q3 FY2020Sep 30, 2020$238.75M+446.4%
Q2 FY2020Jun 30, 2020$70.46M+105.6%
Q1 FY2020Mar 31, 2020$85.81M+112.8%
Q4 FY2019Dec 31, 2019$36.39M-16.4%
Q3 FY2019Sep 30, 2019$43.70M-8.7%
Q2 FY2019Jun 30, 2019$34.28M-33.1%
Q1 FY2019Mar 31, 2019$40.33M-28.4%
Q4 FY2018Dec 31, 2018$43.55M+3113.9%
Q3 FY2018Sep 30, 2018$47.87M–
Q2 FY2018Jun 30, 2018$51.21M–
Q1 FY2018Mar 31, 2018$56.32M–
Q4 FY2017Dec 31, 2017$1.36M–

More BioXcel Therapeutics figures

See a number that looks wrong?